Clinical trial
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With…
NCT00275067 · Northwestern University, Other · Unknown status
Key facts
| NCT number | NCT00275067 |
|---|---|
| Title | Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery |
| Official title | A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination With Radiation Therapy for Patients With Malignant Gliomas |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Cephalon Industry CTI BioPharma |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Radiation |
| Interventions | arsenic trioxide, temozolomide, radiation therapy |
| Enrollment | 50 |
| Start date | May 1, 2005 |
| Primary completion | May 1, 2021 |
| Completion | May 1, 2021 |
| First posted | Jan 11, 2006 |
| Last update posted | Feb 25, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: